Phase II study of fixed dose-rate gemcitabine plus S-1 as a second-line treatment for advanced biliary tract cancer.

Satoshi KobayashiMakoto UenoKazuya SugimoriChigusa MorizaneYasushi KojimaKuniyasu IrieYoshihiro GodaManabu MorimotoShinichi Ohkawa

Published in: Cancer chemotherapy and pharmacology (2017)

Second-line fixed dose-rate gemcitabine plus S-1 was not sufficiently effective and tolerable in patients with advanced biliary tract cancer refractory to gemcitabine or gemcitabine plus cisplatin.

Keyphrases

locally advanced
phase ii study
papillary thyroid
rectal cancer
squamous cell
radiation therapy
open label
lymph node metastasis
randomized controlled trial